The disclosure relates, in some aspects, to compositions and methods fortreatment of diseases associated with aberrantlysosomal function, for example Parkinson's disease and Gaucher disease. Insome embodiments, the disclosure provides expressionconstructs comprising a transgene encoding one or more inhibitory nucleicacids targeting SCNA or a portion thereof, THEM106B ora portion thereof, or any combination of the foregoing. In some embodiments,the disclosure provides methods of Parkinson's diseaseby administering such expression constructs to a subject in need thereof.
